GlassScriptPhysician profile
Annmarie Johnson
NPI 1083177000
$2,903.55
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $775 · 2023: $1,168 · 2024: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $318.58 | 2022-2023 | Barostim Neo System |
| Genentech USA, INC. | $273.50 | 2023 | Tecentriq, Lunsumio |
| Merck Sharp & Dohme LLC | $238.28 | 2024 | Keytruda |
| Insmed, INC. | $229.18 | 2021-2022 | |
| Argenx US, INC. | $217.70 | 2022-2023 | Vyvgart |
| Kite Pharma, INC. | $196.50 | 2021-2022 | |
| Abbvie INC. | $187.46 | 2023 | |
| Neurocrine Biosciences, INC. | $156.50 | 2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $129.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.86 | 2024 | Quviviq |
| Genzyme Corporation | $124.80 | 2024 | |
| Mylan Specialty L.P. | $123.39 | 2021 | |
| Novocure INC. | $118.02 | 2022 | |
| Janssen Biotech, INC. | $106.16 | 2023 | Tecvayli, Carvykti, Darzalex |
| Medtronic, INC. | $100.00 | 2023 | Venaseal |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $92.04 | 2021 | |
| Sobi, INC | $86.95 | 2023 | |
| Boston Scientific Corporation | $80.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annmarie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.